UBS Group
POM

UBS Group’s Pomdoctor Ltd POM Stock Holding History

UBS Group’s Portfolio POM Stock Details POM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.28K Sell
925
-11,367
-92% -$58.3K ﹤0.01% 8952
2025
Q4 		$65.3K Buy
+12,292
New +$802K ﹤0.01% 7095

Other funds holding POM

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group's POM Position: Q1 2026 in Review

UBS Group reduced its Pomdoctor Ltd (POM) stake by 92% in Q1 2026, selling an estimated $58.3K and leaving 925 shares worth $4.28K. The position accounts for ﹤0.01% of the portfolio, ranked #8952.

UBS Group first reported a position in POM in Q4 2025 and has held it in 2 quarters since. The position peaked at $65.3K in Q4 2025. 10 funds tracked by Wall St. Rank hold POM as of Q1 2026.

  • UBS Group held 925 shares of Pomdoctor Ltd worth $4.28K as of Q1 2026.
  • UBS Group sold 11,367 Pomdoctor Ltd shares in Q1 2026, an estimated $58.3K.
  • Pomdoctor Ltd made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8952 holding.
  • UBS Group first reported a position in Pomdoctor Ltd in Q4 2025 and has held it in 2 quarters since.
  • UBS Group's Pomdoctor Ltd position peaked at $65.3K in Q4 2025.
  • 10 funds tracked by Wall St. Rank held Pomdoctor Ltd as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.